title: The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation.
abstract: We aimed to evaluate the clinical efficacy of r-LH supplementation to r-FSH in patients with suboptimal response to ovarian stimulation undergoing assisted reproduction with GnRH-a downregulation and stimulation with r-FSH. One-hundred thirty-seven patients were included in the study; among them 52 showed normal ovarian response to stimulation and composed the control group (Group 1), and 85 showed suboptimal response to stimulation and were divided into two groups. For Group 2 (n = 50), 75 IU/L r-LH was added to the treatment, for Group 3 (n = 35) r-FSH dose was increased by 75 IU/L. IVF results were compared between the groups. Implantation rates were 34.8% in control group, and 36.1% and 15% in LH supplementation group and increased-dose r-FSH group, respectively. Implantation rates were statistically significantly higher in Groups 1 and 2 compared to Group 3 (p < 0.02). Pregnancy rate was noticed in 64.7% of Group 1, 57.8% of Group 2 and at 32.4% of Group 3. Pregnancy rate was significantly higher in Group 2 than Group 3 (p < 0.05). r-LH supplementation is an option for improving IVF outcome in patients with suboptimal ovarian response to ovulation induction with r-FSH during GnRH agonist down-regulation. Particularly, r-LH is recommended as it may have a beneficial action on implantation in selected group.
authors.affiliation: Department of Obstetrics and Gynecology, Minister of Health Sisli Etfal Training&Research Hospital , Istanbul , Turkey and.
authors.forename: Fatma
authors.initials: F
authors.lastname: Yazıcı Yılmaz
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Görkemli
authors.forename: Mehmet Cengiz
authors.initials: MC
authors.lastname: Çolakoğlu
authors.forename: Murat
authors.initials: M
authors.lastname: Aktan
authors.forename: Kazım
authors.initials: K
authors.lastname: Gezginç
mesh_terms: D000328:Adult; D015536:Down-Regulation; D010064:Embryo Implantation; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007247:Infertility, Female / Q000453:epidemiology / Q000628:therapy*; D007986:Luteinizing Hormone / Q000627:therapeutic use*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000627:therapeutic use; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
keywords: GnRH agonist long protocol; r-LH; suboptimal ovarian response